AbbVie Inc. (ABBV) Stock

AbbVie Inc. operates globally as a leading pharmaceutical company engaged in the discovery, development, manufacturing, and distribution of innovative therapies. Known for its comprehensive portfolio, AbbVie offers a range of treatments addressing various medical conditions. Key products include Humira, widely prescribed for autoimmune diseases like rheumatoid arthritis and Crohn's disease, and Skyrizi, used for moderate to severe plaque psoriasis and psoriatic arthritis. The company also develops advanced therapies such as Rinvoq, a JAK inhibitor for rheumatoid arthritis and other inflammatory disorders, and Imbruvica, targeting blood cancers.

Additionally, AbbVie is at the forefront of medical aesthetics with facial injectables and skincare products, and it provides solutions in neurology, including Vraylar for bipolar disorder and Ubrelvy for acute migraine treatment. The company's commitment extends to ophthalmology with products like Lumigan/Ganfort for glaucoma management and Restasis for dry eye syndrome. Further expanding its therapeutic offerings, AbbVie addresses gastrointestinal disorders, hepatitis C, and endocrinology with medications like Mavyret for HCV and Linzess for irritable bowel syndrome.

Founded in 2012 and headquartered in North Chicago, Illinois, AbbVie continues to drive innovation through strategic collaborations with leading biopharmaceutical companies. These partnerships enhance research capabilities and broaden therapeutic options, reinforcing AbbVie's position as a trusted leader in the pharmaceutical industry dedicated to improving patient outcomes worldwide.